F S&P 500
5,314.50 +10.50 (+0.20%) F Dow Jones
38,842.00 +55.00 (+0.14%) F Nasdaq
18,776.50 +75.50 (+0.40%) E-mini Russell 2000 Index Futur
2,040.60 +3.10 (+0.15%) Petróleo
73.39 +0.14 (+0.19%) Oro
2,353.80 +6.40 (+0.27%)
Kancera AB (publ) (3EE0.F)
Kancera AB (publ)
Karolinska Institutet Science Park
Nanna Svarts väg 4
Solna 171 65
Sweden
46 8 50 12 60 80
https://www.kancera.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 3
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Thomas Olin Ph.D. | Executive VP, CSO & Director | 3.57M | N/D | 1958 |
| Mr. Peter Selin | Chief Executive Officer | N/D | N/D | 1973 |
| Mr. Hans Richter | Chief Financial Officer | N/D | N/D | 1949 |
| Dr. Niclas Brynne | Head of Clinical Development | N/D | N/D | 1961 |
| Dr. Markus Jerling M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1952 |
Descripción
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Gestión corporativa
La calificación ISS Governance QuickScore de Kancera AB (publ) a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
